BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2642488)

  • 1. The effects of SMS 201-995 (sandostatin) on metabolic profiles in insulin-dependent diabetes mellitus.
    Grossman LD; Shumak SL; George SR; Singer W; Zinman B
    J Clin Endocrinol Metab; 1989 Jan; 68(1):63-7. PubMed ID: 2642488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment with somatostatin analog SMS 201-995 potentiates growth hormone (GH) responsiveness to GH-releasing factor in short children.
    Dickerman Z; Guyda H; Tannenbaum GS
    J Clin Endocrinol Metab; 1993 Sep; 77(3):652-7. PubMed ID: 8257527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients.
    Lamberts SW; Oosterom R; Neufeld M; del Pozo E
    J Clin Endocrinol Metab; 1985 Jun; 60(6):1161-5. PubMed ID: 2860119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
    Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of somatostatin analogue SMS 201-995 in non-insulin-dependent diabetes.
    Davies RR; Miller M; Turner SJ; Watson M; McGill A; Orskov H; Alberti KG; Johnston DG
    Clin Endocrinol (Oxf); 1986 Dec; 25(6):739-47. PubMed ID: 2888547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin analog SMS 201-995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas.
    Rios MS; Navascues I; Saban J; Ordoñez A; Sevilla F; Del Pozo E
    J Clin Endocrinol Metab; 1986 Nov; 63(5):1071-4. PubMed ID: 2876005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous subcutaneous octreotide infusion: dose-response relationships between metabolic effects and octreotide clearance in patients with insulin-dependent (type 1) diabetes.
    Osei K; O'Dorisio TM; Malarkey WB; Cataland S
    J Lab Clin Med; 1991 Jul; 118(1):56-64. PubMed ID: 2066644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of acetylsalicylic acid on blood glucose, plasma FFA, glycerol, 3-hydroxybutyrate, alanine, C-peptide, glucagon and growth hormone responses to arginine in insulin-dependent diabetics.
    Giugliano D; Luyckx AS; Lefebvre PJ
    Diabete Metab; 1980 Mar; 6(1):39-46. PubMed ID: 6989660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients.
    Scheen AJ; Gillet J; Rosenthaler J; Guiot J; Henrivaux P; Jandrain B; Lefèbvre PJ
    Diabetologia; 1989 Nov; 32(11):801-9. PubMed ID: 2687064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin pretreatment enhances growth hormone (GH) responsiveness to GH-releasing hormone: a potential new diagnostic approach to GH deficiency.
    Tzanela M; Guyda H; Van Vliet G; Tannenbaum GS
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2487-94. PubMed ID: 8675565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a somatostatin derivative (SMS 201-995) on postprandial hyperglycemia in insulin-dependent diabetics studied by means of a closed-loop device.
    Nosari I; Lepore G; Querci F; Maglio ML; Sileo F; Pagani G
    J Endocrinol Invest; 1989 Jun; 12(6):413-7. PubMed ID: 2671112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of the somatostatin analogue SMS 201-995 on carbohydrate homeostasis of insulin-dependent diabetics as assessed by the artificial endocrine pancreas.
    Hadjidakis DJ; Halvatsiotis PG; Ioannou YJ; Mavrokefalos PJ; Raptis SA
    Diabetes Res Clin Pract; 1988 Jul; 5(2):91-8. PubMed ID: 2901329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin.
    Gerich JE; Lorenzi M; Bier DM; Tsalikian E; Schneider V; Karam JH; Forsham PH
    J Clin Invest; 1976 Apr; 57(4):875-84. PubMed ID: 820717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of somatostatin (SRIH) and a SRIH analog, SMS 201-995, on the secretion of growth hormone and thyroid-stimulating hormone in man.
    Williams TC; Kelijman M; Crelin WC; Downs TR; Frohman LA
    J Clin Endocrinol Metab; 1988 Jan; 66(1):39-45. PubMed ID: 2891721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin-analogue (SMS 201-995) in insulin-dependent diabetes mellitus.
    Spinas GA; Bock A; Keller U
    Diabetes Care; 1985; 8(5):429-35. PubMed ID: 2865093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of growth hormone and somatomedin C by long-acting somatostatin analog SMS 201-995 in type I diabetes mellitus.
    Plewe G; Noelken G; Krause U; Beyer J; del Pozo E
    Horm Res; 1987; 27(1):7-12. PubMed ID: 2887504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early morning hyperglycemia in insulin-dependent diabetes: acute and sustained effects of cholinergic blockade.
    Atiea JA; Creagh F; Page M; Owens DR; Scanlon MF; Peters JR
    J Clin Endocrinol Metab; 1989 Aug; 69(2):390-5. PubMed ID: 2666430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of the somatostatin analogue octreotide on growth hormone secretion in insulin-dependent diabetics without residual insulin secretion.
    Wurzburger MI; Prelevic GM; Sonksen PH; Balint-Peric LA
    Horm Metab Res; 1992 Jul; 24(7):329-32. PubMed ID: 1516889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic effects of long-acting somatostatin analogue (sandostatin) in type I diabetic patients on conventional therapy.
    Osei K; O'Dorisio TM; Malarkey WB; Craig EL; Cataland S
    Diabetes; 1989 Jun; 38(6):704-9. PubMed ID: 2656340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.